Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Famotidine Launch Delayed By Pepcid AC Pediatric Exclusivity

This article was originally published in The Tan Sheet

Executive Summary

Private label famotidine 10 mg products will not launch until after April 15 due to FDA's Nov. 21 decision to grant J&J/Merck an additional six months of marketing exclusivity for Pepcid AC after reviewing pediatric data submitted by the firm.
Advertisement

Related Content

Pediatric Exclusivity Could Be Out-Licensed To Other Sponsors, FDA Suggests
Pediatric Exclusivity Could Be Out-Licensed To Other Sponsors, FDA Suggests
Pediatric Exclusivity Could Be Out-Licensed To Other Sponsors, FDA Suggests
Private label famotidine
Private label famotidine
Private label famotidine
OTC Prilosec For Chronic Use Needs Explicit Labeling, NDAC, GDAC Advise
J&J/Merck Pepcid AC Orally Disintegrating Tablets In The Works
W-L Allergy/Cold Brands Help Offset Struggling Zantac 75 Sales In 1Q
W-L Allergy/Cold Brands Help Offset Struggling Zantac 75 Sales In 1Q

Topics

Advertisement
UsernamePublicRestriction

Register

PS091934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel